Iterum Therapeutics PLC (ITRM)
| Market Cap | 191.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -52.01M |
| Shares Out | 179.14M |
| EPS (ttm) | -2.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $1.07 |
| Previous Close | $1.03 |
| Change ($) | 0.04 |
| Change (%) | 3.88% |
| Day's Open | 1.04 |
| Day's Range | 1.03 - 1.10 |
| Day's Volume | 5,200,107 |
| 52-Week Range | 0.45 - 6.02 |
DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and...
Biotech penny stocks continue to see momentum; should you add these 3 to your watchlist? The post Top Biotech Penny Stocks to Buy?
Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Inf...
Iterum Therapeutics plc (NASDAQ: ITRM) shares dropped after the company in an SEC filing disclosed that the FDA needs additional time to review its sulopenem application. The application seeks approval...
DUBLIN, Ireland and CHICAGO, April 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a...
Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...
The fact that other antibiotic makers have declared bankruptcy in recent years is a negative sign for Iterum. Long-term investors should avoid ITRM stock.
Fundamentally, ITRM stock is an excellent play on multi-drug resistance pathogen solutions but you must also be aware of its extreme boom-bust cycles. The post Iterum Therapeutics' Science Won't Prevent...
Patrick Heron to leave the Board
- -NDA for Oral Sulopenem has PDUFA date of July 25, 2021 -- - -Cash Runway into First Half of 2023 —
DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a...
It's encouraging that Iterum's oral antibiotic has blockbuster status potential, but the basic earnings data on ITRM stock signal caution. The post Unfavorable Earnings Profile Doesn't Bode Well for Ite...
DUBLIN, Ireland and CHICAGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...
DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...
Iterum Therapeutics (ITRM) stock is taking off on Tuesday with heavy trading even without any news coming from the company. The post ITRM Stock: 7 Things for Investors to Know About Iterum Therapeutics ...
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...
DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...
-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 --
DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral an...
--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities --
Trading on Nasdaq Capital Market is expected to begin on December 23, 2020 Trading on Nasdaq Capital Market is expected to begin on December 23, 2020
Bilayer tablet patent application could provide U.S. patent coverage for Iterum's commercial formulation through 2039, if granted Bilayer tablet patent application could provide U.S. patent coverage for...
Iterum Therapeutics (ITRM) is in the news Thursday following news of massive stakes in the company pushing ITRM stock higher. The post Iterum Therapeutics News: Why ITRM Stock Is Rocketing Higher Today ...
-- F irst O ral Penem in the U . S . and First New Oral Treatment for uUTI s in Over 20 Years , if approved - - - - Potential Approval Q3 2021 with Priority Review --
NDA Filing Expected Q4 2020 NDA Filing Expected Q4 2020
DUBLIN, Ireland and CHICAGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibioti...
Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies
Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies
--Preparing to Submit NDA in Q4-- DUBLIN, Ireland and CHICAGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused ...
DUBLIN, Ireland and CHICAGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation or...
DUBLIN, Ireland and CHICAGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation or...
DUBLIN, Ireland and CHICAGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...
DUBLIN, Ireland and CHICAGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...
--Meeting with FDA Scheduled for end of Q3-- --Meeting with FDA Scheduled for end of Q3--
DUBLIN, Ireland and CHICAGO, July 13, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...
DUBLIN, Ireland and CHICAGO, June 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics to...
Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens
DUBLIN, Ireland and CHICAGO, June 15, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant p...
DUBLIN, Ireland and CHICAGO, June 03, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibio...
Study did not meet its primary endpoint Study did not meet its primary endpoint
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors --
DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...
Topline results expected in Q1 2020 Topline results expected in Q1 2020
Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.
DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic to ...
Topline results expected in Q1 2020 Topline results expected in Q1 2020
Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -14.97% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the ...
Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
| Industry Biotechnology | IPO Date May 25, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol ITRM |
Analyst Forecasts
According to 4 analysts, the average rating for ITRM stock is "Sell." The 12-month stock price forecast is 2.25, which is an increase of 110.28% from the latest price.